Sol Gel Technologies Ltd
NASDAQ:SLGL
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Sol Gel Technologies Ltd
Operating Income
Sol Gel Technologies Ltd
Operating Income Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Operating Income | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Sol Gel Technologies Ltd
NASDAQ:SLGL
|
Operating Income
-$7.5m
|
CAGR 3-Years
23%
|
CAGR 5-Years
24%
|
CAGR 10-Years
N/A
|
|
|
Teva Pharmaceutical Industries Ltd
TASE:TEVA
|
Operating Income
$4.1B
|
CAGR 3-Years
9%
|
CAGR 5-Years
5%
|
CAGR 10-Years
-1%
|
|
|
PolyPid Ltd
NASDAQ:PYPD
|
Operating Income
-$33m
|
CAGR 3-Years
5%
|
CAGR 5-Years
-5%
|
CAGR 10-Years
N/A
|
|
|
Mediwound Ltd
NASDAQ:MDWD
|
Operating Income
-$25.3m
|
CAGR 3-Years
-50%
|
CAGR 5-Years
-23%
|
CAGR 10-Years
-2%
|
|
|
S
|
Seach Medical Group Ltd
TASE:SEMG
|
Operating Income
₪14.8m
|
CAGR 3-Years
36%
|
CAGR 5-Years
1%
|
CAGR 10-Years
N/A
|
|
|
R
|
Rekah Pharmaceutical Industry Ltd
TASE:REKA
|
Operating Income
-₪7.2m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Sol Gel Technologies Ltd
Glance View
Sol-Gel Technologies Ltd. is a clinical-stage dermatology company, which engages in the identification, development, and commercialization of topical dermatological drug products for the treatment of skin diseases. The firm is focused on identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases. The Company’s offers a range of products twins, sirs-t, and vered. The firm is designed its proprietary, silica-based microencapsulation technology platform to enhance the tolerability and stability of topical drugs while maintaining their efficacy. Topical drugs often struggle to balance achieving both high efficacy and high tolerability. Its technology platform entraps active ingredients in an inert, inorganic silica shell, which creates an unnoticeable barrier between the active ingredient and the skin.
See Also
What is Sol Gel Technologies Ltd's Operating Income?
Operating Income
-7.5m
USD
Based on the financial report for Dec 31, 2025, Sol Gel Technologies Ltd's Operating Income amounts to -7.5m USD.
What is Sol Gel Technologies Ltd's Operating Income growth rate?
Operating Income CAGR 5Y
24%
Over the last year, the Operating Income growth was 37%. The average annual Operating Income growth rates for Sol Gel Technologies Ltd have been 23% over the past three years , 24% over the past five years .
